



Integrating NGS with CRISPR for Drug Discovery

Topudyati Mondal*

Abstract

synergy in the field of drug discovery, offering unprecedented opportunities for accelerating the development of novel therapeutics. NGS provides comprehensive genomic data, enabling the identification of disease-associated

fail or succeed in specific contexts. This can lead to more informed drug development strategies and reduce the risk of late-stage failures.

5. A :

By streamlining the identification and validation of drug targets, and by elucidating drug mechanisms, the integration of NGS and CRISPR can significantly accelerate the preclinical development phase. Faster validation of targets and mechanisms enables quicker progression to clinical trials [9], potentially bringing new treatments to patients more rapidly.

6. :

While the combination of NGS and CRISPR holds immense promise, it also raises ethical and technical considerations. e